Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations

Molecular Pharmaceutics

Volumn 11, Issue 6, 2014, Pages 1889-1896

  Inoue, Naoto ^a   Takai, Eisuke ^a   Arakawa, Tsutomu ^b   Shiraki, Kentaro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b ALLIANCE PROTEIN LABORATORIES   (United States)

Author keywords

antibody; arginine; protein protein interaction; viscosity

Indexed keywords

AMYLASE; ARGININE; BOVINE IMMUNOGLOBULIN; CHYMOTRYPSIN A; GLOBULAR PROTEIN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; ALPHA-CHYMOTRYPSIN; ANTIBODY; CHYMOTRYPSIN; IMMUNOGLOBULIN; PROTEIN AGGREGATE; SOLUTION AND SOLUBILITY;

ALKALINITY; AQUEOUS SOLUTION; ARTICLE; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROTEIN INTERACTION; STATIC ELECTRICITY; VISCOMETRY; VISCOSITY; ANIMAL; BOVINAE; CHEMISTRY; DRUG EFFECTS; HUMAN; MEDICINAL CHEMISTRY; PH; PROCEDURES; SOLUTION AND SOLUBILITY;

ALPHA-AMYLASES; ANIMALS; ANTIBODIES; ARGININE; CATTLE; CHEMISTRY, PHARMACEUTICAL; CHYMOTRYPSIN; GAMMA-GLOBULINS; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN G; PROTEIN AGGREGATES; SOLUTIONS; VISCOSITY;

EID: 84901754058     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp5000218     Document Type: Article

References (77)

1. Pavlou, A. K.; Belsey, M. J. The therapeutic antibodies market to 2008 Eur. J. Pharm. Biopharm. 2005, 59, 389-396
2. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 2001, 344, 783-792
3. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer N. Engl. J. Med. 2004, 350, 2335-2342
4. Lipsky, P. E.; van der Heijde, D. M., St; Clair, E. W.; Furst, D. E.; Breedveld, F. C.; Kalden, J. R.; Smolen, J. S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G. R.; Maini, R. N. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis N. Engl. J. Med. 2000, 343, 1594-1602
5. Polman, C. H.; O'Connor, P. W.; Havrdova, E.; Hutchinson, M.; Kappos, L.; Miller, D. H.; Phillips, J. T.; Lublin, F. D.; Giovannoni, G.; Wajgt, A.; Toal, M.; Lynn, F.; Panzara, M. A.; Sandrock, A. W. AFFIRM Investigators. A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis N. Engl. J. Med. 2006, 354, 899-910
6. Sliwkowski, M. X.; Mellman, I. Antibody therapeutics in cancer Science 2013, 341, 1192-1198
7. Yadav, S.; Laue, T. M.; Kalonia, D. S.; Singh, S. N.; Shire, S. J. The influence of charge distribution on self-association and viscosity behavior of monoclonal antibody solutions Mol. Pharmaceutics 2012, 9, 791-802
8. Shire, S. J. Formulation and manufacturability of biologics Curr. Opin. Biotechnol. 2009, 20, 708-714
9. Yang, M. X.; Shenoy, B.; Disttler, M.; Patel, R.; McGrath, M.; Pechenov, S.; Margolin, A. L. Crystalline monoclonal antibodies for subcutaneous delivery Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 6934-6939
10. Harn, N.; Allan, C.; Oliver, C.; Middaugh, C. R. Highly Concentrated Monoclonal Antibody Solutions: Direct Analysis of Physical Structure and Thermal Stability J. Pharm. Sci. 2007, 96, 532-546
11. Du, W.; Klibanov, A. M. Hydrophobic salts markedly diminish viscosity of concentrated protein solutions Biotechnol. Bioeng. 2011, 108, 632-636
12. Galush, W. J.; Le, L. N.; Moore, J. M. Viscosity Behavior of High-Concentration Protein Mixtures J. Pharm. Sci. 2012, 101, 1012-1020
13. Salinas, B. A.; Sathish, H. A.; Bishop, S. M.; Harn, N.; Carpenter, J. F.; Randolph, T. W. Understanding and modulating opalescence and viscosity in a monoclonal antibody formulation J. Pharm. Sci. 2010, 99, 82-93
14. Saluja, A.; Badkar, A. V.; Zeng, D. L.; Nema, S.; Kalonia, D. S. Application of high-frequency rheology measurements for analyzing protein-protein interactions in high protein concentration solutions using a model monoclonal antibody (IgG 2) J. Pharm. Sci. 2006, 95, 1967-1983
15. Yadav, S.; Liu, J. U. N.; Shire, S. J.; Kalonia, D. S. Specific interactions in high concentration antibody solutions resulting in high viscosity J. Pharm. Sci. 2010, 99, 1152-1168
16. Yadav, S.; Shire, S. J.; Kalonia, D. S. Viscosity Behavior of High-Concentration Monoclonal Antibody Solutions: Correlation with Interaction Parameter and electroviscous effects J. Pharm. Sci. 2012, 101, 998-1011
17. Liu, J.; Nguyen, M. D. H.; Andya, J. D.; Shire, S. J. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution J. Pharm. Sci. 2005, 94, 1928-1940
18. Kanai, S.; Liu, J.; Patapoff, T. W.; Shire, S. J. Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity J. Pharm. Sci. 2008, 97, 4219-4227
19. Guo, Z.; Chen, A.; Nassar, R. A.; Helk, B.; Mueller, C.; Tang, Y.; Gupta, K.; Klibanov, A. M. Structure-Activity Relationship for Hydrophobic Salts as Viscosity-Lowering Excipients for Concentrated Solutions of Monoclonal Antibodies Pharm. Res. 2012, 29 (11) 3102-3109
20. Sharma, V. K.; Chih, H.-W; Mrsny, R. J.; Daugherty, A. L. The Formulation and Delivery of Monoclonal Antibodies. In Therapeutic Monoclonal Antibodies: From Bench to Clinic; An, Z., Ed.; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2009; Chapter 30.
21. Tomita, S.; Yoshikawa, H.; Shiraki, K. Arginine Controls Heat-Induced Cluster-Cluster Aggregation of Lysozyme at Around the Isoelectric Point Biopolymers 2011, 95, 695-701
22. Hamada, H.; Takahashi, R.; Noguchi, T.; Shiraki, K. Differences in the effects of solution additives on heat- and refolding-induced aggregation Biotechnol. Prog. 2008, 24, 436-443
23. Shiraki, K.; Kudou, M.; Fujiwara, S.; Imanaka, T.; Takagi, M. Biophysical effect of amino acids on the prevention of protein aggregation J. Biochem. 2002, 132, 591-595
24. Matsuoka, T.; Hamada, H.; Matsumoto, K.; Shiraki, K. Indispensable Structure of Solution Additives to Prevent Inactivation of Lysozyme for Heating and Refolding Biotechnol. Prog. 2009, 25, 1515-1524
25. Fujimoto, A.; Hirano, A.; Shiraki, K. Ternary system of solution additives with arginine and salt for refolding of beta-galactosidase Protein J. 2010, 29, 161-166
26. Hamada, H.; Shiraki, K. L-argininamide improves the refolding more effectively than L-arginine J. Biotechnol. 2007, 130, 153-160
27. Shikiya, Y.; Tomita, S.; Arakawa, T.; Shiraki, K. Arginine inhibits proteins adsorption on polystyrene surface PLoS One 2013, 8, e70762
28. Takai, E.; Yoshizawa, S.; Ejima, D.; Arakawa, T.; Shiraki, K. Synergistic Solubilization of Porcine Myosin in Physiological Salt Solution by Arginine Int. J. Biol. Macromol. 2013, 62, 647-651
29. Hirano, A.; Arakawa, T.; Shiraki, K. Arginine increases the solubility of coumarin: comparison with salting-in and salting-out additives J. Biochem. 2008, 144, 363-369
30. Ito, L.; Shiraki, K.; Matsuura, T.; Okumura, M.; Hasegawa, K.; Baba, S.; Yamaguchi, H.; Kumasaka, T. High-resolution X-ray analysis reveals binding of arginine to aromatic residues of lysozyme surface: implication of suppression of protein aggregation by arginine Protein Eng., Des. Sel. 2011, 24, 269-274
31. Hirano, A.; Kameda, T.; Shinozaki, D.; Arakawa, T.; Shiraki, K. Molecular dynamics simulation of the arginine-assisted solubilization of caffeic acid: intervention in the interaction J. Phys. Chem. B 2013, 117, 7518-7527
32. Arakawa, T.; Hirano, A.; Shiraki, K.; Kita, Y.; Koyama, A. H. Stabilizing and destabilizing effects of arginine on deoxyribonucleic acid Int. J. Biol. Macromol. 2010, 46, 217-222
33. Ariki, R.; Hirano, A.; Arakawa, T.; Shiraki, K. Arginine increases the solubility of alkyl gallates through interaction with the aromatic ring J. Biochem. 2011, 149, 389-394
34. Hirano, A.; Tokunaga, H.; Tokunaga, M.; Arakawa, T.; Shiraki, K. The solubility of nucleobases in aqueous arginine solutions Arch. Biochem. Biophys. 2010, 497, 90-96
35. Hirano, A.; Kameda, T.; Arakawa, T.; Shiraki, K. Arginine-assisted solubilization system for drug substances: solubility experiment and simulation J. Phys. Chem. B 2010, 114, 13455-13462
36. Vagenende, V.; Han, A. X.; Mueller, M.; Trout, B. L. Protein-associated cation clusters in aqueous arginine solutions and their effects on protein stability and size ACS Chem. Biol. 2013, 8, 416-422
37. Schneider, C. P.; Shukla, D.; Trout, B. L. Arginine and the Hofmeister Series: the role of ion-ion interactions in protein aggregation suppression J. Phys. Chem. B 2011, 115, 7447-7458
38. Shukla, D.; Trout, B. L. Interaction of arginine with proteins and the mechanism by which It inhibits aggregation J. Phys. Chem. B 2010, 114, 13426-13438
39. Schneider, C. P.; Trout, B. L. Investigation of cosolute-protein preferential interaction coefficients: New insight into the mechanism by which arginine inhibits aggregation J. Phys. Chem. B 2009, 113, 2050-2058
40. Arakawa, T.; Ejima, D.; Tsumoto, K.; Obeyama, N.; Tanaka, Y.; Kita, Y.; Timasheff, S. N. Suppression of protein interactions by arginine: a proposed mechanism of the arginine effects Biophys. Chem. 2007, 127, 1-8
41. Arakawa, T.; Tsumoto, K. The effects of arginine on refolding of aggregated proteins: not facilitate refolding, but suppress aggregation Biochem. Biophys. Res. Commun. 2003, 304, 148-152
42. Hamada, H.; Arakawa, T.; Shiraki, K. Effect of additives on protein aggregation Curr. Pharm. Biotechnol. 2009, 10, 400-407
43. Ishibashi, M.; Tsumoto, K.; Tokunaga, M.; Ejima, D.; Kita, Y.; Arakawa, T. Is arginine a protein-denaturant? Protein Expression Purif. 2005, 42, 1-6
44. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Arakawa, T. Solubilization of active green fluorescent protein from insoluble particles by guanidine and arginine Biochem. Biophys. Res. Commun. 2003, 312, 1383-1386
45. Tsumoto, K.; Umetsu, M.; Kumagai, I.; Ejima, D.; Philo, J. S.; Arakawa, T. Role of arginine in protein refolding, solubilization, and purification Biotechnol. Prog. 2004, 20, 1301-1308
46. Tsumoto, K.; Ejima, D.; Kita, Y.; Arakawa, T. Review: Why is arginine effective in suppressing aggregation? Protein Pept. Lett. 2005, 12, 613-619
47. Arakawa, T.; Tsumoto, K.; Kita, Y.; Chang, B.; Ejima, D. Biotechnology applications of amino acids in protein purification and formulations Amino Acids 2007, 33, 587-605
48. Bowen, M. N.; Liu, J.; Patel, A. R. Compositions and methods useful for reducing the viscosity of protein-containing formulations. US Patent 130058958 A1, 2013.
49. Jezek, J.; Rides, M.; Derham, B.; Moore, J.; Cerasoli, E.; Simler, R.; Perez-Ramirez, B. Viscosity of concentrated therapeutic protein compositions Adv. Drug Delivery Rev. 2011, 63, 1107-1117
50. Chari, R.; Jerath, K.; Badkar, A. V.; Kalonia, D. S. Long- and short-range electrostatic interactions affect the rheology of highly concentrated antibody solutions Pharm. Res. 2009, 26, 2607-2618
51. Kita, Y.; Arakawa, T.; Lin, T. Y.; Timasheff, S. N. Contribution of the surface free energy perturbation to protein-solvent interactions Biochemistry 1994, 33, 15178-15189
52. Arakawa, T.; Timasheff, S. N. The mechanism of action of Na glutamate, lysine HCl, and piperazine-N,N′-bis(2-ethanesolfonic acid) in the stabilization of tubulin and microtubule formation J. Biol. Chem. 1984, 259, 4979-4986
53. Arakawa, T.; Timasheff, S. N. Preferential interactions of proteins with salts in concentrated solutions Biochemistry 1982, 21, 6545-6552
54. Arakawa, T.; Timasheff, S. N. Abromal solubility behavior of β-lactoglobulin: salting-in by glycine and NaCl Biochemistry 1987, 26, 5147-5153
55. Arakawa, T.; Timasheff, S. N. Preferential interactions of proteins with solvent components in aqueous amino acid solution Arch. Biochem. Biophys. 1983, 224, 169-177
56. Arakawa, T.; Timasheff, S. N. The stabilization of proteins by osmolytes Biophys. J. 1985, 47, 411-414
57. Inoue, N.; Takai, E.; Arakawa, T.; Shiraki, K. Arginine and Lysine Reduce the High Viscosity of Serum Albumin Solutions for Pharmaceutical Injection J. Biosci. Bioeng. 2014, 117 (5) 539-543
58. Stokes, R. H.; Mills, R. Viscosity of electrolytes and related properties; Pergamon Press: New York, 1965.
59. Goldsack, D. E.; Franchetto, R. The viscosity of concentrated electrolyte solution. I. Concentration dependence at fixed temperature Can. J. Chem. 1977, 55, 1062-1072
60. Mooney, M. The viscosity of a concentrated suspension of spherical particles J. Colloid Sci. 1951, 6, 162-170
61. Ross, P. D.; Minton, A. P. Hard quasispherical model for the viscosity of hemoglobin solutions Biochem. Biophys. Res. Commun. 1977, 76, 971-976
62. Connolly, B. D.; Petry, C.; Yadav, S.; Demeule, B.; Ciaccio, N.; Moore, J. M. R.; Shire, S. J.; Gokarn, Y. R. Weak Interactions Govern the Viscosity of Concentrated Antibody Solutions: High-Throughput Analysis Using the Diffusion Interaction Parameter Biophys. J. 2012, 103, 69-78
63. Fahrner, R. L.; Whitney, D. H.; Vanderlaan, M.; Blank, G. S. Performance comparison of protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies Biotechnol. Appl. Biochem. 1999, 30, 121-128
64. Björck, L.; Kronvall, G. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent J. Immunol. 1984, 133, 969-974
65. Arakawa, T.; Philo, J. S.; Tsumoto, K.; Yumioka, R.; Ejima, D. Elution of antibodies from a Protein-A column by aqueous arginine solutions Protein Expression Purif. 2004, 36, 244-248
66. Ejima, D.; Yumioka, R.; Arakawa, T.; Tsumoto, K. Arginine as an effective additive in gel permeation chromatography J. Chromatogr. A 2005, 1094, 49-55
67. Lilyestrom, W. G.; Shire, S. J.; Scherer, T. M. Influence of the Cosolute Environment on IgG Solution Structure Analyzed by Small-Angle X-ray Scattering J. Phys. Chem. B 2012, 116, 9611-9618
68. Lee, E. Z.; Huh, Y. S.; Jun, Y. S.; Won, H. J.; Hong, Y. K.; Park, T. J.; Lee, S. Y.; Hong, W. H. Removal of bovine serum albumin using solid-phase extraction with in-situ polymerized stationary phase in a microfluidic device J. Chromatogr. A 2008, 1187, 11-17
69. Benesch, J.; Mano, J. F.; Reis, R. L. Analysing protein competition on self-assembled mono-layers studied with quartz crystal microbalance Acta Biomater. 2010, 6, 3499-3505
70. Bauer, P. I.; Buki, K. G.; Hakam, A.; Kun, E. Macromolecular association of ADP-ribosyltransferase and its correlation with enzymic activity Biochem. J. 1990, 270, 17-26
71. Bigelow, C. C. On the average hydrophobicity of proteins and the relation between it and protein structure J. Theor. Biol. 1967, 16, 187-211
72. Saksena, S.; Zydney, A. L. Effect of solution pH and ionic strength on the separation of albumin from immunoglobulins (IgG) by selective filtration Biotechnol. Bioeng. 1994, 43, 960-968
73. Doumas, B. T.; Peters, T., Jr. Serum and urine albumin: a progress report on their measurement and clinical significance Clin. Chim. Acta 1997, 258, 3-20
74. Yadav, S.; Shire, S. J.; Kalonia, D. S. Viscosity analysis of high concentration bovine serum albumin aqueous solutions Pharm. Res. 2011, 28, 1973-1983
75. Fukada, H.; Takahashi, K.; Sturtevant, J. M. Differential scanning calorimetric study of the thermal unfolding of Taka-amylase A from Aspergillus oryzae Biochemistry 1987, 26, 4063-4068
76. 2O) J. Cryst. Growth 1989, 98, 721-730
77. De Diego, T.; Lozano, P.; Gmouh, S.; Vaultier, M.; Iborra, J. L. Fluorescence and CD spectroscopic analysis of the alpha-chymotrypsin stabilization by the ionic liquid, 1-ethyl-3-methylimidazolium bis[(trifluoromethyl)sulfonyl]amide Biotechnol. Bioeng. 2004, 88, 916-924